Pharmacogenetics of OATP (SLC21/SLCO), OAT and OCT (SLC22) and PEPT (SLC15) transporters in the intestine, liver and kidney

Pharmacogenomics

Volumn 9, Issue 5, 2008, Pages 597-624

  Zaïr, Zoulikha M ^a   Eloranta, Jyrki J ^a   Stieger, Bruno ^a   Kullak Ublick, Gerd A ^a  

^a UNIVERSITY HOSPITAL ZURICH   (Switzerland)

Author keywords

Drug transporter; Estrone 3 sulfate; Farnesoid X receptor; Organic anion trasporter protein; Organic anion transporting polypeptide; Organic cation transporter; PEPT1; Pharmacokinetics; SNP; Statin

Indexed keywords

ADEFOVIR; ATORVASTATIN; BESTATIN; BETA LACTAM ANTIBIOTIC; BROMSULFOPHTHALEIN; CAPTOPRIL; CEFADROXIL; CEFALEXIN; CIMETIDINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENALAPRIL; ESTRADIOL; GLYCYLSARCOSINE; GLYSAR; LEVODOPA; MEMBRANE PROTEIN; METFORMIN; METHOTREXATE; ORGANIC ANION TRANSPORTER; ORGANIC CATION TRANSPORTER; ORGANIC CATION TRANSPORTER 1; ORGANIC CATION TRANSPORTER 2; PEPTIDE TRANSPORTER 1; PRAVASTATIN; PROTEIN SLC22A6; PROTEIN SLCO1B3; PROTEIN SLCO2B1; RIFAMPICIN; ROSUVASTATIN; SIMVASTATIN; UNINDEXED DRUG;

ACTIVE TRANSPORT; DRUG ABSORPTION; DRUG ELIMINATION; DRUG LIVER LEVEL; DRUG METABOLISM; DRUG UPTAKE; ETHNIC DIFFERENCE; GENE FREQUENCY; GENETIC POLYMORPHISM; GENETIC VARIABILITY; GENOTYPE; HETEROZYGOSITY; HUMAN; INTESTINE ABSORPTION; KIDNEY TUBULE ABSORPTION; LIVER CLEARANCE; PHARMACOGENETICS; PHENOTYPE; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW;

ANIMALS; HUMANS; INTESTINES; KIDNEY; LIVER; ORGANIC ANION TRANSPORTERS; PHARMACOGENETICS;

EID: 44949099300     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/14622416.9.5.597     Document Type: Review

References (109)

1. Kullak-Ublick GA, Stieger B, Meler PJ: Enterohepatic bile salt transporters in normal physiology and liver disease. Gastroenterology 126, 322-342 (2004).
2. Glaeser H, Bailey DG, Dresser GK et al.: Intestinal drug transporter expression and the impact of grapefruit juice in humans. Clin. Pharmacol. Ther. 81, 362-370, (2007).
3. Meier Y, Eloranta JJ, Darimont J et al.: Regional distribution of solute carrier RNA expression along the human intestinal tract. Drug Metab. Dispot. 35, 590-594 (2007).
4. Chan LM, Lowes S, Hirst BH: The ABCs of drug transport in intestine and liver: efflux proteins limiting drug absorption and bioavailability. Eur. J. Pharm. Sci. 21, 25-51 (2004).
5. Zuber R, Anzenbacherova E, Anzenbacher P: Cytochromes P450 and experimental models of drug metabolism. J. Cell. Mol. Med. 6, 189-198 (2002).
6. Cascorbi I: Role of pharmacogenetics of ATP-binding cassette transporters in the pharmacokinetics of drugs. Pharmacol. Ther. 112, 457-473 (2006).
7. Halestrap, AP, Meredith D: The SLC16 gene family - from moriocarboxylate transporters (MCTS) to aromatic amino acid transporters and beyond. Pflugers Arch. 447, 619-628 (2004).
8. Evseenko D, Paxton JW, Keelan JA: Active transport across the human placenta: impact on drug efficacy and toxicity. Expert Opin. Drug Metab. Toxicol. 2, 51-69 (2006).
9. Suzuki T, Onogawa T Asano, N et al.: Identification and characterization of novel rat and human gonad-specific organic anion transporters. Mol. Endocrinol. 17, 1203-1215 (2003).
10. Hilgendorf C, Ahlin G, Seithel A, Artursson P, Ungell AL, Karisson J: Expression of thirty-six drug transporter genes in human intestine, liver, kidney, and organotypic cell lines. Drug Metab. Dispos. 35, 1333-1340 (2007).
11. Freeman TC, Bentsen BS, Thwaltes DT, Simmons NL: H+/di-tripeptide transporter (PepT1) expression in the rabbit intestine. Pflugers Arch. 430, 394-400 (1995).
12. Brandsch M, Brandsch C, Ganapathy ME, Chew CS, Ganapathy V, Leibach FH: Influence of proton and essential histidyl residues on the transport kinetics of the H'/peptide cotransport systems in intestine (PEPT 1) and kidney (PEPT 2). Biochim. Biophys. Acta 1324, 251-262 (1997).
13. Dantzig AH, Bergin L: Uptake of the cephalosporin, cephalexin, by a dipeptide transport carrier in the human intestinal cell line, Caco-2. Biochim. Biophys. Acta 1027, 211-217 (1990).
14. Satake M, Enjoh M, Nakamura Y et al.: Transepithelial transport of the bioactive tripeptide Val-Pro-Pro, in human intestinal Caco-2 cell monolayers. Biosci. Biotechnol. Biochem. 66, 378-384 (2002).
15. Anderle P, Nielsen CU, Pinsonneault J, Krog PL, Brodin B, Sadee W: Genetic variants of the human dipeptide transporter PEPT1. J. Pharmacol. Exp. Ther. 316, 636-646 (2006).
16. Zhang EY, Fu DJ, Pak YA et al.: Genetic polymorphisms in human proton-dependent dipeptide transporter PEPT1: implications for the functional role of Pro586. J. Pharmacol. Exp. Ther. 310, 437-445 (2004).
17. +-oligopeptide cotransporter hPEPT1. J. Physiol. 574, 149-166 (2006).
18. Yabuuchi H, Tamai I, Nezu J et al.: Novel membrane transporter OCTN1 mediates multispecific, bidirectional, and pH-dependent transport of organic cations. J. Pharmacol. Exp. Ther. 289, 768-773 (1999).
19. Wu X, Huang W, Prasad PD et al.: Functional characteristics and tissue distribution pattern of organic cation transporter 2 (OCTN2), an organic cation/carnitine transporter. J. Pharmacol. Exp. Ther. 290, 1482-1492 (1999).
20. Leung E, Hong J, Fraser AG, Merriman TR, Vishnu P, Krissansen GW: Polymorphisms in the organic cation transporter genes SLC22A4 and SLC22A5 and Crohn's disease in a New Zealand Caucasian cohort. Immunol. Cell. Biol. 84, 233-236 (2006).
21. Palmieri O, Latiano A, Valvano R et al.: Variants of OCTN1-2 cation transporter genes are associated with both Crohn's disease and ulcerative colitis. Aliment. Pharmacol. Ther. 23, 497-506 (2006).
22. Peltekova VD, Wintle RF, Rubin LA et al.: Functional variants of OCTN cation transporter genes are associated with Crohn disease. Nat. Genet. 36, 471-475 (2004).
23. Urban TJ, Brown C, Castro RA et al.: Effects of genetic variation in the novel organic cation transporter, OCTN1, on the renal clearance of gabapentin. Clin. Pharmacol. Ther. 83(3), 416-421 (2008).
24. Hosoyamada M, Sekine T, Kanai Y, Endou H: Molecular cloning and functional expression of a multispecific organic anion transporter from human kidney. Am. J. Physiol. 276, F122-F128 (1999).
25. Kimura H, Takeda M, Narikawa S, Enomoto A, Ichida K, Endou H: Human organic anion transporters and human organic cation transporters mediate renal transport of prostaglandins. J. Pharmacol. Exp. Ther. 301, 293-298 (2002).
26. Babu E, Takeda M, Narikawa S et al.: Human organic anion transporters mediate the transport of tetracycline. Jpn J. Pharmacol. 88, 69-76 (2002).
27. Xu G, Bhatnagar V, Wen G, Hamilton BA, Eraly SA, Nigam SK: Analyses of coding region polymorphisms in apical and basolateral human organic anion transporter (OAT) genes i OAT1 (NKT), OAT2, OAT3, OAT4, URAT (RST)]. Kidney Int. 68, 1491-1499 (2005).
28. König J, Seithel A, Gradhand U, Fromm MF: Pharmacogenomics of human OATP transporters. Naunyn Schmiedebergs Arch. Pharmacol. 372, 432-443 (2006).
29. Hagenbuch B, Meier PJ: The superfamily of organic anion transporting polypeptides. Biochim. Biophys. Acta 1609, 1-18 (2003).
30. Hagenbuch B, Meier PJ: Organic anion transporting polypeptides of the OATP/SLC21 family: phylogenetic classification as OATP/SLCO superfamily, new nomenclature and molecular/functional properties. Pflugers Arch. 447, 653-665 (2004).
31. Mikkaichi T, Suzuki T, Tanemoto M, Ito S, Abe T: The organic anion transporter (OATP) family. Drug Metab. Pharmacokinet. 19, 171-179 (2004).
32. Gründemann D, Gorboulev V, Gambaryan S, Veyhl M, Koepsell H: Drug excretion mediated by a new prototype of polyspecific transporter. Nature 372, 549-552 (1994).
33. Koepsell H, Lips K, Volk C: Polyspecific organic cation transporters: structure, function, physiological roles, and biopharmaceutical implications. Pharm. Res. 24, 1227-1251 (2007).
34. Meyer-Wentrup F, Karbach U, Gorboulev V, Arndt P, Koepsell H: Membrane localization of the electrogenic cation transporter rOCT1 in rat liver. Biochem. Biophys. Res. Commun. 248, 673-678 (1998).
35. Gorboulev V, Ulzheimer JC, Akhoundova A et al.: Cloning and characterization of two human polyspecific organic cation transporters. DNA Cell Biol. 16, 871-881 (1997).
36. Zhang L, Dresser MJ, Gray AT, Yost SC, Terashita S. Giacomini KM: Cloning and functional expression of a human liver organic cation transporter. Mol. Pharmacol. 51, 913-921 (1997).
37. Sakata T, Anzai N, Shin HJ et al.: Novel single nucleotide polymorphisms of organic cation transporter 1 (SLC22A1) affecting transport functions. Biochem. Biophys. Res. Commun. 313, 789-793 (2004).
38. Itoda M, Saito Y, Maekawa K et al.: Seven novel single nucleotide polymorphisms in the human SLC22A1 gene encoding organic cation transporter 1 (OCT1). Drug Metab. Pharmacokinet. 19, 308-312 (2004).
39. Takeuchi A, Motohashi H, Okuda M. Inui K: Decreased function of genetic variants, Pro283Leu and Arg287Gly, in human organic cation transporter hOCT1. Drug Metab, Pharmacokinet. 18, 409-412 (2003).
40. Shu Y, Leabman MK, Feng B et al.: Evolutionary conservation predicts function of variants of the human organic cation transporter, OCT1. Proc. Natl Acad. Sci. USA 100, 5902-5907 (2003).
41. Leabman MK, Huang CC, DeYoung J et al.: Natural variation in human membrane transporter genes reveals evolutionary and functional constraints. Proc. Natl Acad. Sci. USA 100, 5896-5901 (2003).
42. Kerb R, Brinkmann U, Chatskala N et al.: Identification of genetic variations of the human organic cation transporter hOCT1 and their functional consequences. Pharmacogenetics 12, 591-595 (2002).
43. Kang HJ, Song IS, Shin HJ et al.: Identification and functional characterization of genetic variants of human organic cation transporters in a Korean population. Drug Metab. Dispos. 35, 667-675 (2007).
44. Wang DS, Jonker JW, Kato Y, Kusuhara H, Schinkel AH, Sugiyama Y: Involvement of organic cation transporter 1 in hepatic and intestinal distribution of metformin. J. Pharmacol. Exp. Ther. 302, 510-515 (2002).
45. Shu Y, Sheadown SA, Brown C et al.: Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J. Clin. Invest. 117, 1422-1431 (2007).
46. Shikata E, Yamamoto R, Takane H et al.: Human organic cation transporter (OCT1 and OCT2) gene polymorphisms and therapeutic effects of metformin. J. Hum. Genet. 52, 117-122 (2007).
47. Kullak-Ublick GA, Ismair MG, Stieger B et al.: Organic anion-transporting polypeptide B (OATP-B) and its functional comparison with three other OATPs of human liver. Gastroenterology 120, 525-533 (2001).
48. König J, Cui Y, Nies AT, Keppler D: A novel human organic anion transporting polypeptide localized to the basolateral hepatocyte membrane. Am. J. Physiol. Gastrointest. Liver Physiol. 278, G156-G164 (2000).
49. Abe T. Kakyo M, Tokui T et al.: Identification of a novel gene family encoding human liver-specific organic anion transporter LST-1. J. Biol. Chem. 274, 17159-17163 (1999).
50. Niemi M, Schaeffeler E, Lang T et al.: High plasma pravastatin concentrations are associated with single nucleotide polymorphisms and haplotypes of organic anion transporting polypeptide-C (OATP-C, SLCO1B1). Pharmacogenetics 14, 429-440 (2004).
51. Nozawa T, Nakajima M, Tamai I et al.: Genetic polymorphisms of human organic anion transporters OATP-C (SLC21A6) and OATP-B (SLC21A9): allele frequencies in the Japanese population and functional analysis. J. Pharmacol. Exp. Ther. 302, 804-813 (2002).
52. Tirona RG, Leake BE Merino G, Kim RB: Polymorphisms in OATP-C: identification of multiple allelic variants associated with altered transport activity among European - and African-Americans. J. Biol. Chem. 276, 35669-35675 (2001).
53. Choi JH, Lee MG, Cho JY, Lee JE, Kim KH, Park K: Influence of OATP1B1 genotype on the pharmacokinetics of rosuvastatin in Koreans. Clin. Pharmacol. Ther. 83, 251-257 (2008).
54. Iwai M, Suzuki H, Ieiri I, Otsubo K, Sugiyama Y. Functional analysis of single nucleotide polymorphisms of hepatic organic anion transporter OATP1B1 (OATP-C). Pharmacogenetics 14, 749-757 (2004).
55. Hsiang B, Zhu Y, Wang Z et al.: A novel human hepatic organic anion transporting polypeptide (OATP2). Identification of a liver-specific human organic anion transporting polypeptide and identification of rat and human hydroxymethylglutaryl-CoA reductase inhibitor transporters. J. Biol. Chem. 274, 37161-37168 (1999).
56. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K: Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet. Genomics 15, 513-522 (2005).
57. Nishizato Y, Ieiri I, Suzuki H et al.: Polymorphisms of OATP-C (SLC21A6) and OAT3 (SLC22A8) genes: consequences for pravastatin pharmacokinetics. Clin. Pharmacol. Ther. 73, 554-565 (2003).
58. Tachibana-Iimori R, Tabara Y, Kusuhara H et al.: Effect of genetic polymorphism of OATP-C (SLCO1B1) on lipid-lowering response to HMG-CoA reductase inhibitors. Drug Metab. Pharmacokinet. 19, 375-380 (2004).
59. Mwinyi J, Johne A, Bauer S, Roots I, Gerloff T: Evidence for inverse effects of OATP-C (SLC21A6) 5 and 1b haplotypes on pravastatin kinetics. Clin. Pharmacol. Ther. 75, 415-421 (2004).
60. Morimoto K, Oishi T, Ueda S, Ueda M, Hosokawa M, Chiba K: A novel variant allele of OATP-C (SLCO1B1) found in a Japanese patient with pravastatin-induced myopathy. Drug Metab. Pharmacokinet. 19, 453-455 (2004).
61. Gerloff T, Schaefer M, Mwinyi J et al.: Influence of the SLCO1B1*1b and *5 haplotypes, on pravastatin's cholesterol lowering capabilities and basal sterol serum levels. Naunyn Schmiedebergs Arch. Pharmacol. 373, 45-50 (2006).
62. Ho RH, Tirona RG, Leake BF et al.: Drug and bile acid transporters in rosuvastatin hepatic uptake: function, expression, and pharmacogenetics. Gastroenterology 130, 1793-1806 (2006).
63. Chung JY, Cho JY, Yu KS et al.: Effect of OATP1B1 (SLCO1B1) variant alleles on the pharmacokinetics of pitavastatin in healthy volunteers. Clin. Pharmacol. Ther. 78, 342-350 (2005).
64. Lee E, Ryan S, Birmingham B et al.: Rosuvastatin pharmacokinetics and pharmacogenetics in white and Asian subjects residing in the same environment. Clin. Pharmacol. Ther. 78, 330-341 (2005).
65. Zhang W, He YJ, Han CT et al.: Effect of SLCO1B1 genetic polymorphism on the pharmacokinetics of nateglinide. Br. J. Clin. Pharmacol. 62, 567-572 (2006).
66. Niemi M, Backman JT, Kajosaari LI et al.: Polymorphic organic anion transporting polypeptide 1B1 is a major determinant of repaglinide pharmacokinetics. Clin. Pharmacol. Ther. 77, 468-478 (2005).
67. Ieiri I, Suzuki H, Kimura M et al.: Influence of common variants in the pharmacokinetic genes (OATP-C, UGT1A1, and MRP2) on serum bilirubin levels in healthy subjects. Hepatol. Res. 30, 91-95 (2004).
68. Michalski C, Cui Y, Nies AT et al.: A naturally occurring mutation in the SLC21A6 gene causing impaired membrane localization of the hepatocyte uptake transporter. J. Biol. Chem. 277, 43058-43063 (2002).
69. Iida A, Saito S, Sekine A et al.: Catalog of 258 single-nucleotide polymorphisms (SNPs) in genes encoding three organic anion transporters, three organic anion-transporting polypeptides, and three NADH:ubiquinone oxidoreductase flavoproteins. J. Hum. Genet. 46, 668-683 (2001).
70. Furihata T, Satoh T, Yamamoto N, Kobayashi K, Chiba K: Hepatocyte nuclear factor 1 α is a factor responsible for the interindividual variation of OATP1B1 mRNA levels in adult Japanese livers. Pharm. Res. 24, 2327-2332 (2007).
71. Jung D, Hagenbuch B, Gresh L, Pontoglio M, Meier PJ, Kullak-Ublick GA: Characterization of the human OATP-C (SLC21A6) gene promoter and regulation of liver-specific OATP genes by hepatocyte nuclear factor 1 α. J. Biol. Chem. 276, 37206-37214 (2001).
72. König J, Cui Y, Nies AT, Keppler D: Localization and genomic organization of a new hepatocellular organic anion transporting polypeptide. J. Biol. Chem. 275, 23161-23168 (2000).
73. Abe T, Unno M, Onogawa T et al.: LST-2, a human liver-specific organic anion transporter, determines methotrexate sensitivity in gastrointestinal cancers. Gastroenterology 120, 1689-1699 (2001).
74. Tsujimoto M, Hirata S, Dan Y, Ohtani H, Sawada Y: Polymorphisms and linkage disequilibrium of the OATP8 (OATPIB3) gene in Japanese subjects. Drug Metab. Pharmacokinet. 21, 165-169 (2006).
75. Letschert K, Keppler D, Konig J: Mutations in the SLCO1B3 gene affecting the substrate specificity of the hepatocellular uptake transporter OATPIB3 (OATP8). Pharmacogenetics 14, 441-452 (2004).
76. Smith NF, Marsh S, Scott-Horton TJ et al.: Variants in the SLCO1B3 gene: interethnic distribution and association with paclitaxel pharmacokinetics. Clin. Pbarmacol. Ther. 81, 76-82 (2007).
77. Ismair MG, Stieger B. Cattori V et al.: Hepatic uptake of cholecystokinin octapeptide by organic anion-transporting polypeptides OATP4 and OATP8 of rat and human liver. Gastroenterology 121, 1185-1190 (2001).
78. Jung D, Podvinec M, Meyer UA et al.: Human organic anion transporting polypeptide 8 promoter is transactivated by the farnesoid X receptor/bile acid receptor. Gastroenterology 122, 1954-1966 (2002).
79. Marzolini C, Tirona RG, Gervasini G et al.: A common polymorphism in the bile acid receptor farnesoid X receptor is associated with decreased hepatic target gene expression. Mol. Endocrinol. 21, 1769-1780 (2007).
80. van Mil SW, Milona A, Dixon PH et al.: Functional variants of the central bile acid sensor FXR identified in intrahepatic cholestasis of pregnancy. Gastroenterology 133, 507-516 (2007).
81. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I: Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J. Pharmacol. Exp. ther: 306, 703-708 (2003).
82. Nozawa T. Imai K, Nezu J, Tsuji A, Tamai I: Functional characterization.of pH-sensitive organic anion transporting polypeptide OATP-B in human. J. Pharmacol. Exp. Ther. 308, 438-445 (2004).
83. Tamai I, Nezu J, Uchino H et al.: Molecular identification and characterization of novel members of the human organic anion transporter (OATP) family. Biochem. Biophys. Res. Commun. 273, 251-260 (2000).
84. Otsuka M, Matsumoto T, Morimoto R, Arioka S, Omote H, Moriyama Y: A human transporter protein that mediates the final excretion step for toxic organic cations. Proc. Natl Acad. Sci. USA 102, 17923-17928 (2005).
85. + /organic cation antiporter, kidney-specific multidrug and toxin extrusion 2. J. Am. Soc. Nephrol. 17, 2127-2135 (2006).
86. +)-organic cation antiporters. Biochem. Pharmacol. 74, 359-371 (2007).
87. Yonezawa A, Masuda S, Yokoo, S, Katsura T, Inui K: Cisplatin and oxaliplatin, but not carboplatin and nedaplatin, are substrates for human organic cation transporters (SLC22A1-3 and multidrug and toxin extrusion family). J. Pharmacol. Exp. Ther. 319, 879-886 (2006).
88. Yokoo S, Yonezawa A, Masuda S, Fukatsu A, Katsura T, Inui K: Differential contribution of organic cation transporters, OCT2 and MATE1, in platinum agent-induced nephrotoxicity. Biochem. Pharmacol. 74, 477-487 (2007).
89. Aslamkhan AG, Han YH, Yang XP, Zalups RK, Pritchard JB: Human renal organic anion transporter 1-dependent uptake and toxicity of mercuric-thiol conjugates in Madin-Darby canine kidney cells. Mol. Pharmacol. 63, 590-596 (2003).
90. Lopez-Nieto CE, You G, Bush KT, Barros EJ, Beier DR, Nigam SK: Molecular cloning and characterization of NKT, a gene product related to the organic cation transporter family that is almost exclusively expressed in the kidney. J. Biol. Chem. 272, 6471-6478 (1997).
91. Bleasby K, Hall LA, Perry JL, Mohrenweiser HW, Pritchard JB: Functinal consequences of single nucleotide polymorphisms in the human organic anion transporter hOAT1 (SLC22A6). J. Pharmacol. Exp. Ther. 314, 923-931 (2005).
92. Fujita T, Brown C, Carlson EJ et al.: Functional analysis of polymorphisms in the organic anion transporter, SLC22A6 (OAT1). Pharmacogenet. Genomics 15, 201-209 (2005).
93. Erdman AR, Mangravite LM, Urban TJ et al.: The human organic anion transporter 3 (OAT3; SLC22A8): genetic variation and functional genomics. Am. J. Physiol. Renal Physiol. 290, F905-F912 (2006).
94. Motohashi H, Sakurai Y, Saito H et al.: Gene expression levels and immunolocalization of organic ion transporters in the human kidney. J. Am. Soc. Nephrol. 13, 866-874 (2002).
95. Urakami Y, Akazawa M, Saito H, Okuda M, Inui K: cDNA cloning, functional characterization, and tissue distribution of an alternatively spliced variant of organic cation transporter hOCT2 predominantly expressed in the human kidney. J. Am. Soc. Nephrol. 13, 1703-1710 (2002).
96. Fukushima-Uesaka H, Maekawa K, Ozawa S et al.: Fourteen novel single nucleotide polymorphisms in the SLC22A2 gene encoding human organic cation transporter (OCT2). Drug Metab. Pharmacokinet. 19, 239-244 (2004).
97. Saito S, Iida A, Sekine A et al.: Catalog of 238 variations among six human genes encoding solute carriers (hSLCs) in the Japanese population. J. Hum. Genet. 47, 576-584 (2002).
98. Leabman MK, Huang CC, Kawamoto M et al.: Polymorphisms in a human kidney xenobiotic transporter, OCT2, exhibit altered function. Pharmacogenetics 12, 395-405 (2002).
99. Kimura N, Masuda S, Tanihara Y et al.: Metformin is a superior substrate for renal organic cation transporter OCT2 rather than hepatic OCT1. Drug Metab. Pharmacokinet. 20, 379-386 (2005).
100. Nigam SK, Bush KT, Bhatnagar V: Drug and toxicant handling by the OAT organic anion transporters in the kidney and other tissues. Nat. Clin. Pract. Nephrol. 3, 443-448 (2007).
101. Anzai N, Kanai Y, Endou H: Organic anion transporter family: current knowledge. J. Pharmacol. Sci. 100, 411-426 (2006).
102. Robertson EE, Rankin GO: Human renal organic anion transporters: characteristics and contributions to drug and drug metabolite excretion. Pharmacol. Ther. 109, 399-412 (2006).
103. Shitara Y, Sato H, Sugiyama Y: Evaluation of drug-drug interaction in the hepatobiliary and renal transport of drugs. Annu. Rev. Pharmacol. Toxicol. 45, 689-723 (2005).
104. Marzolini C, Tirona RG, Kim RB: Pharmacogenomics of the OATP and OAT families. Pharmacogenomics 5, 273-282 (2004).
105. Wright SH: Role of organic cation transporters in the renal handling of therapeutic agents and xenobiotics. Toxicol. Appl. Pharmacol. 204, 309-319 (2005).
106. Maeda T, Goto A, Kobayashi D, Tamari I: Transport of organic cations across the blood-testis barrier. Mol. Pharm. 4, 600-607 (2007).
107. Pinsonneault J, Nielsen CU, Sadee W. Genetic variants of the human H+/ dipeptide transporter PEPT2: analysis of haplotype functions. J. Pharmacol. Exp. Ther. 311, 1088-1096 (2004).
108. Tirona RG, Leake BF, Wolkoff AW, Kim RB: Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnane X receptor activation. J. Pharmacol. Exp. Ther. 304, 223-228 (2003).
109. Nozawa T, Minami H, Sugiura S, Tsuji A, Tamai I: Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab. Dispos. 33, 434-439 (2005).